Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Operating Cash Flow
Cash generated by the company's core business operations during the period.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $22.61M (cash outflow) rose 40.8% year over year, ahead of the +26.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 60.5% from the prior quarter. Over 3 fiscal years it compounded at +29.9% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.8% holds above the trailing-twelve-month pace of +26.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (62.34M) USD
- Year-over-year change
- -31.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (62.34M) | -31.9% |
| FY2024 | 2024-12-31 | (47.27M) | -19.6% |
| FY2023 | 2023-12-31 | (39.53M) | -39.1% |
| FY2022 | 2022-12-31 | (28.42M) | +1.7% |
| FY2021 | 2021-12-31 | (28.91M) | — |
Operating Cash Flow vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 operating cash flow of $68.89M is the 9th largest of the 11 companies compared; the peer median is $117.87M.
- Its year-over-year change of +26.2% is the 6th highest of 11, against a peer median of +22.3%.
- Over three fiscal years its annual growth of +29.9% compares with a peer median of +10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $140.5M | -32.5% | -2.3% | 363.1% | |
| LTM Mar 2026 | $131.7M | +141.5% | +11.1% | 2295.2% | |
| LTM Mar 2026 | $127.99M | +14.3% | +119.6% | 350.7% | |
| LTM Mar 2026 | $126.51M | +124.0% | — | 58.1% | |
| LTM Mar 2026 | $109.23M | -44.6% | -12.2% | — | |
| LTM Mar 2026 | $101.54M | +2.2% | +13.9% | 5037.0% | |
| LTM Mar 2026 | $77.73M | +29.8% | +20.6% | 534.6% | |
| LTM Mar 2026 | $68.89M | +26.2% | +29.9% | — | |
| LTM Mar 2026 | $53.61M | +71.4% | — | 23.6% | |
| LTM Mar 2026 | $45.31M | +27.4% | +9.6% | — | |
| Peer median (excluding ELDN) | $117.87M | +22.3% | +10.3% | 363.1% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| Deferred Income Tax | (2.35M) | 0 | 0 | 431K | 5K |
| Stock-Based Compensation | 7.9M | 8.15M | 6.55M | 13.12M | 10.45M |
| Change in Working Capital | (152K) | 2.37M | (4.92M) | 8.71M | 7.65M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | 2.08M | (2.6M) | 7.75M | 6.72M |
| Other Working Capital | (2.3M) | 287K | (2.32M) | 959K | 928K |
| Other Non-Cash Items | 0 | 48.65M | 75.01M | (33.71M) | (35.15M) |
| Operating Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (78.29M) | (156.13M) | (161.13M) |
| Sales of Investments | 0 | 0 | 33M | 85.82M | 171.93M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (45.29M) | (70.31M) | 10.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (449K) | 0 | 33.02M | 133.31M | 53.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 215K | 0 |
| Financing Cash Flow | (449K) | 0 | 33.02M | 133.52M | 53.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.36M) | (28.42M) | (51.8M) | 15.94M | 2.26M |
| Free Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.